Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. demonstrated robust performance with a 31% year-over-year increase in net revenue to $209.4 million, exceeding both internal forecasts and consensus estimates. The company's flagship product, Jornay, exhibited strong growth with total prescriptions increasing by 20% year-over-year, contributing to significant revenue growth of 28.2% sequentially, driven by improvements in gross-to-net metrics. Additionally, management raised its 2025 revenue guidance, projecting revenues between $745 million and $760 million, indicating a strong outlook for future financial performance within the specialty pharmaceutical sector.

Bears say

Collegium Pharmaceutical Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Sales for key products, including Xtampza ER and Belbuca, have shown a downward trend with prescription decreases in recent quarters, leading to concerns about overall revenue growth. Additionally, the company is at risk from potential generic competition, unfavorable reimbursement dynamics, and execution risks, which could adversely impact its commercial trajectory and profitability in the future.

Collegium Pharmaceutical (COLL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 5 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.